Bayer's Leadership Prepares For First Innovative Drug Launch In China Ahead Of U.S.
This article was originally published in The Pink Sheet Daily
Speedier action by Chinese regulators than by their U.S. counterparts could become common as Bayer Schering institutes its new policy of launching simultaneous clinical trials in the U.S., the EU, and China, exec says.
You may also be interested in...
Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population
BEIJING - The heads of Germany's Bayer Schering Pharma AG and the Polish biotech firm Bioton, which produces human recombinant insulin, met in the Chinese capital this week to sign an agreement that sets the stage for Bayer to market the biopharmaceutical SciLin across China
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.